DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
de Vries TI, Eikelboom JW, Bosch J. , et al.
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Eur Heart J 2019;
40 (46) 3771-3778
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.